MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Alcon Inc

Închisă

SectorSănătate

89.7 -2.86

Rezumat

Modificarea prețului

24h

Curent

Minim

89.26

Maxim

92.53

Indicatori cheie

By Trading Economics

Venit

21M

284M

Vânzări

48M

2.5B

P/E

Medie Sector

46.307

63.778

EPS

0.72

Randament dividend

0.28

Marjă de profit

11.351

Angajați

25,599

EBITDA

56M

397M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+15.91% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.28%

2.39%

Următoarele câștiguri

13 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

5.9B

47B

Deschiderea anterioară

92.56

Închiderea anterioară

89.7

Sentimentul știrilor

By Acuity

50%

50%

180 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Alcon Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 mar. 2025, 21:22 UTC

Achiziții, Fuziuni, Preluări

Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment

24 mar. 2025, 12:36 UTC

Achiziții, Fuziuni, Preluări

Alcon to Buy Lensar in Deal Worth Up to $430 Million

12 nov. 2024, 18:48 UTC

Câștiguri
Principalele dinamici ale pieței

Alcon Posts Higher 3Q Sales and Profit, Lowers 2024 Sales View

26 mar. 2025, 21:55 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk

26 mar. 2025, 20:33 UTC

Achiziții, Fuziuni, Preluări

Aurion Board Appoints Arnaud Lacoste as CEO of Aurion

26 mar. 2025, 20:32 UTC

Achiziții, Fuziuni, Preluări

Alcon: Aurion Will Operate as a Separate Company With Full Support From Alcon to Advance Its Clinical-Stage Allogeneic Cell Therapy Asset

26 mar. 2025, 20:32 UTC

Achiziții, Fuziuni, Preluări

Leverages Alcon's Global Scale With Aurion's Cell Therapy Expertise to Accelerate U.S. Phase 3 Development in Fall of 2025 >ALC.EB

26 mar. 2025, 20:31 UTC

Achiziții, Fuziuni, Preluări

Alcon Acquires Interest in Aurion to Advance Innovative Cell Therapy for Corneal Endothelial Disease >ALC.EB

26 mar. 2025, 20:31 UTC

Achiziții, Fuziuni, Preluări

Alcon Inc. Unit Alcon Research Previously Sued Aurion to Prevent It From Going Public

26 mar. 2025, 20:31 UTC

Achiziții, Fuziuni, Preluări

Alcon Acquires Majority Interest in Aurion Biotech >ALC.EB

26 mar. 2025, 20:30 UTC

Achiziții, Fuziuni, Preluări

Alcon Acquires Majority Interest in Aurion Biotech

24 mar. 2025, 12:21 UTC

Achiziții, Fuziuni, Preluări

Alcon to Buy Lensar in Deal Worth Up to $430M

24 mar. 2025, 12:05 UTC

Achiziții, Fuziuni, Preluări

Alcon: Transaction Is Anticipated to Close in Mid-To-Late 2025 >ALC

24 mar. 2025, 12:05 UTC

Achiziții, Fuziuni, Preluări

Alcon: Transaction Represents a Total Consideration of Up to About $430M >ALC

24 mar. 2025, 12:04 UTC

Achiziții, Fuziuni, Preluări

Alcon: Additional Non-Tradeable Contingent Value Right Offering Up to $2.75 Per Shr in Cash, Conditioned on Achievement of 614,000 Cumulative Procedures With LENSAR's Products Between Jan 1, 2026, and Dec 31, 2027 >ALC

24 mar. 2025, 12:04 UTC

Achiziții, Fuziuni, Preluări

Alcon Will Purchase All Outstanding Shrs of LENSAR for $14.00 Per Shr in Cash >ALC

24 mar. 2025, 12:03 UTC

Achiziții, Fuziuni, Preluări

Alcon: Acquisition Includes ALLY Robotic Cataract Laser Treatment System, LENSAR's Proprietary Streamline Software Technology and LENSAR Legacy Laser System >ALC

24 mar. 2025, 12:03 UTC

Achiziții, Fuziuni, Preluări

Alcon Agrees to Acquire LENSAR >ALC

24 mar. 2025, 12:00 UTC

Achiziții, Fuziuni, Preluări

Alcon Agrees To Acquire LENSAR, Inc. >ALC LNSR

25 feb. 2025, 21:33 UTC

Câștiguri

Alcon Sees 2025 Adj EPS $3.15-Adj EPS $3.25 >ALC.EB

25 feb. 2025, 21:33 UTC

Câștiguri

Alcon Sees 2025 Sales $10.2B-$10.4B >ALC.EB

25 feb. 2025, 21:32 UTC

Câștiguri

Alcon: Board Authorized the Repurchase of Up to $750M of the Company's Common Shrs >ALC.EB

25 feb. 2025, 21:31 UTC

Câștiguri

Alcon 4Q EPS 57c >ALC.EB

25 feb. 2025, 21:31 UTC

Câștiguri

Alcon 4Q Rev $2.5B >ALC.EB

17 dec. 2024, 15:05 UTC

Market Talk

Alcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk

12 nov. 2024, 17:38 UTC

Câștiguri

Alcon Narrows 2024 View To Adj EPS $3.00-Adj EPS $3.05 >ALC

12 nov. 2024, 17:38 UTC

Câștiguri

Alcon Had Seen 2024 Sales $9.9B-$10.1B >ALC

12 nov. 2024, 17:37 UTC

Câștiguri

Alcon Cuts 2024 View To Sales $9.8B-$9.9B >ALC

12 nov. 2024, 17:36 UTC

Câștiguri

Alcon 3Q Core Operating Margin 20.6% >ALC

12 nov. 2024, 17:36 UTC

Câștiguri

Alcon 3Q Sales $2.43B >ALC

Comparație

Modificare preț

Alcon Inc Așteptări

Obiectiv de preț

By TipRanks

15.91% sus

Prognoză pe 12 luni

Medie 107.45 USD  15.91%

Maxim 120 USD

Minim 90 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAlcon Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

20 ratings

18

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

90.87 / 92.61Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

180 / 386 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Alcon Inc

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.